Navigation Links
DFB Sells Coria Labs to Valeant Pharmaceuticals
Date:9/17/2008

FORT WORTH, Texas, Sept. 17 /PRNewswire/ -- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., today announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to Valeant Pharmaceuticals International (NYSE: VRX).

Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from DFB Pharmaceuticals, Inc., and other shareholders for $95 million, subject to certain adjustments. The transaction is expected to close following the required approval under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended.

"This merger is an exciting milestone in the evolution of the Coria business," said Mr. Dorman. "Valeant has a commitment to the development and growth of its dermatology business, making it the ideal fit for Coria and its talented workforce here in Fort Worth as well as the field based sales representatives across the country. We see the combination of Coria with Valeant's financial strength as a way to maximize the past success of Coria and provide an outstanding platform to create a leading dermatology franchise."

The Coria transaction will add several marketed dermatology products to Valeant's portfolio, including the CeraVe(R) Skin Care Line, Cloderm(R) Cream for the treatment of dermatoses, Akne-Mycin(R) and Atralin(TM) for the treatment of acne, and Salex(R) for the treatment of hyperkeratotic skin disorders, as well as Tetrix(TM) Cream for the treatment of hand dermatitis which is expected to be launched later this year. In addition, Coria has several products under development, including line extensions for the CeraVe(R) brand product line.

Coria Laboratories was advised by William Blair & Company, L.L.C.

About Valeant

Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com.

About Coria Laboratories, Ltd.

Coria Laboratories, Ltd. is a rapidly growing pharmaceutical company specializing in research, development and marketing of high-quality dermatology products for the treatment of diseases affecting the skin, hair, and nails. Coria Laboratories has a broad portfolio of branded prescription and over-the-counter dermatology products. For more information on Coria Laboratories, visit the web site at: http://www.corialabs.com.

About DFB Pharmaceuticals, Inc.

DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB's business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for wound care indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world's leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton's German subsidiary, Phyton GmbH, which operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation. DFB is on the web at http://www.dfb.com.


'/>"/>
SOURCE DFB Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
4. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
5. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
6. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
9. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... The Academy of Model Aeronautics (AMA) ... 29, 2017, to promote AMA’s programs, member services, and the model aviation hobby. ... but not limited to model aviation and other RC activities. , Thousands are ...
(Date:9/21/2017)... MA (PRWEB) , ... September 21, 2017 , ... ... proprietary clinical client portal. Each relaunch of the portal includes new features that ... and medical device companies seek to remain at the forefront of medical advancements, ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... technology, today announced the election of Paul Hermes, Entrepreneur in Residence at Medtronic, ... , Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia Inc. , a ... provider of whole slide imaging solutions, are hosting a pre-conference workshop at the ... Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):